Intravenous omeprazole prevents rebleeding in peptic ulcer patients with a non-bleeding visible vessel: A preliminary report of a randomized controlled study

Rudy Tan Chua, Hwai Jeng Lin, Kun Wang, Chin Lin Perng, Wen Chin Lo, Chen Hsen Lee, Shou Dong Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)


Background. In patients with peptic ulcer bleeding, acid can enhance platelet disaggregation and cause lysis of the clot. Omeprazole, a potent acid suppressor, may be helpful in reducing their rebleeding rate. Methods. Between March and October 1994, 40 patients with a non-bleeding, visible vessel (NBVV) at ulcer bases were enrolled for study. They were randomized into four groups. Group I (n = 10) patients received cimetidine 300 mg intravenously (i.v.) q6h; Group II (n = 10) patients received heater probe thermocoagulation therapy and cimetidine 300 mg i.v. q6h; Group III (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. qd and Group IV (n = 10) patients received omeprazole 40 mg intravenous bolus initially followed by 40 mg i.v. q12h. Endoscopic examination was done for follow-up, daily, for 1-3 days. Results. Preliminary results showed that the age, initial hemoglobin, ulcer size as well as NBVV size in Groups I-IV were not significantly different (p <0.05). The rebleeding rates were 40% in Group I, 20% in Group II, 20% in Group III and 0% in Group IV. (p <0.05 when Group IV is compared with Group I). Conclusions. Intravenous omeprazole 40 mg given q12h can reduce the rebleeding rate of patients with a NBVV.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalChinese Medical Journal (Taipei)
Issue number2
Publication statusPublished - Feb 1996
Externally publishedYes



  • non-bleeding visible vessel
  • omeprazole
  • peptic ulcer

ASJC Scopus subject areas

  • Medicine(all)

Cite this